[3] Sarfati was appointed Interim Chief Executive of the Cancer Control Agency on 1 December 2019, becoming the permanent chief on 1 July 2020 for what is now known as Te Aho o Te Kahu, Cancer Control Agency.

[9] Sarfati was also involved in the establishment of Peptide Receptor Radionuclide Therapy in New Zealand.

[12] Prior to her appointment, Sarfati was Head of the Department of Public Health and the Director of the Cancer and Chronic Conditions (C3) research group at University of Otago, Wellington.

[14][15] Sarfati is also a member of the International Advisory Committee to Lancet Oncology,[16] IARC's international expert group on social inequalities in cancer,[17] the Board of the International Cancer Benchmarking Project,[18] and she led a Lancet Oncology series on cancer in small island developing states.

In 2019, Sarfati was named NEXT's Woman of the Year for her focus on promoting equitable cancer treatment.